[go: up one dir, main page]

WO1993018769A3 - Nouvelle utilisation d'un derive de quinazoline - Google Patents

Nouvelle utilisation d'un derive de quinazoline Download PDF

Info

Publication number
WO1993018769A3
WO1993018769A3 PCT/JP1993/000307 JP9300307W WO9318769A3 WO 1993018769 A3 WO1993018769 A3 WO 1993018769A3 JP 9300307 W JP9300307 W JP 9300307W WO 9318769 A3 WO9318769 A3 WO 9318769A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
hydroxy
protected
prolactin
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1993/000307
Other languages
English (en)
Other versions
WO1993018769A2 (fr
Inventor
Kimio Esumi
Keizo Sogabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of WO1993018769A2 publication Critical patent/WO1993018769A2/fr
Publication of WO1993018769A3 publication Critical patent/WO1993018769A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On décrit une utilisation d'un composé qui correspond à la formule (I) où R1 et R2 représentent chacun hydrogène, halogène, nitro, amino, amino protégé, hydroxyamino, alkyle inférieur, hydroxy, hydroxy protégé, sulfamoyle, carboxy, carboxy protégé, mercapto, carbonyle hétérocyclique éventuellement substitué, alkyle (inférieur) hétérocyclique éventuellement substitué, alkylthio inférieur, alkyle (inférieur) hydroxy ou alkyle (inférieur) hydroxy protégé; R3 représente aryle ou éventuellement son ou ses substituants appropriés, et A représente alkylène inférieur. Ce composé, ou un de ses sels acceptables sur le plan pharmaceutique se prête au traitement de différentes affections choisies dans le groupe consistant en hypertrophie cardiaque, néphropathies, telles que néphrite ou insuffisance rénale, artériosclérose oblitérante, thrombus obstructif, embole artériel, syndrome de Bürger-Grütz, acrocyanose, engelures, gelures, troubles de l'ovulation entraînant la production de prolactine, tumeur de l'hypophyse entraînant la production de prolactine, rétention lactée puerpérale, galactorrhée puerpérale, hypertrophie distale, gigantisme d'origine hypophysaire, troubles mentaux, maladies cérébro-vasculaires, tachycardie accompagnée d'hypertension sympathique, hyperaldostéronisme, et complications dues au diabète.
PCT/JP1993/000307 1992-03-16 1993-03-15 Nouvelle utilisation d'un derive de quinazoline Ceased WO1993018769A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9205702.5 1992-03-16
GB929205702A GB9205702D0 (en) 1992-03-16 1992-03-16 A new use of a quinazoline derivative

Publications (2)

Publication Number Publication Date
WO1993018769A2 WO1993018769A2 (fr) 1993-09-30
WO1993018769A3 true WO1993018769A3 (fr) 1993-11-25

Family

ID=10712228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1993/000307 Ceased WO1993018769A2 (fr) 1992-03-16 1993-03-15 Nouvelle utilisation d'un derive de quinazoline

Country Status (2)

Country Link
GB (1) GB9205702D0 (fr)
WO (1) WO1993018769A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2157208C2 (ru) * 1997-07-10 2000-10-10 Институт органической и физической химии им. А.Е.Арбузова Казанского научного центра РАН Препарат для лечения отморожений
EP3174868B1 (fr) 2014-08-01 2021-08-25 Nuevolution A/S Composés actifs envers des bromodomaines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436157A1 (fr) * 1990-01-02 1991-07-10 Fujisawa Pharmaceutical Co., Ltd. Dérivés de quinazoline et leur préparation
WO1993005035A1 (fr) * 1991-09-06 1993-03-18 Fujisawa Pharmaceutical Co., Ltd. Derives de quinazoline et leur preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436157A1 (fr) * 1990-01-02 1991-07-10 Fujisawa Pharmaceutical Co., Ltd. Dérivés de quinazoline et leur préparation
WO1993005035A1 (fr) * 1991-09-06 1993-03-18 Fujisawa Pharmaceutical Co., Ltd. Derives de quinazoline et leur preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARDIOVASCULAR DRUGS AND THERAPY vol. 4, no. S1, 1990, pages 73 - 84 C. COBO ET AL. ,V. COTO ET AL. , G.P. VYSSOULIS ET AL. 'EFFECTS OF KETANSERIN ON LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS, REGRESSION OF LEFT VENTRICULAR HYPERTROPHY AND SYSTOLIC FUNCTION IN HYPERTENSIVE PATIENTS DURING LONG-TERM TREATMENT WITH KETANSERIN, LEFT VENTRICULAR HYPERTROPHY REGRESSION AND FUNCTION CHANGES WITH KETANSERIN ...' *
GENERAL PHARMACOLOGY vol. 20, no. 6, 1989, pages 755 - 758 M. MIDOL-MONNET ET AL. 'STUDY ON THE MECHANISM OF 5-HT-INDUCED TACHYCARDIA IN THE PITHED RAT' *
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY vol. 7, no. S7, 1985, pages S70 - S75 S. SAMAN ET AL. 'SEROTONIN AND THE HEART: EFFECTS OF KETANSERIN ON MYOCARDIAL FUNCTION, HEART RATE, AND ARRHYTHMIAS' *

Also Published As

Publication number Publication date
WO1993018769A2 (fr) 1993-09-30
GB9205702D0 (en) 1992-04-29

Similar Documents

Publication Publication Date Title
PL332946A1 (en) 1-phenylpyrazole compounds and their pharmaceutic application
CA2432872A1 (fr) Composes de pyrazole utiles comme inhibiteurs de proteines kinases
WO2000008048A3 (fr) Inhibiteur d'histone déacétylase
EP0487745A4 (en) Pyridine derivative with angiotensin ii antagonism
EP0795548A4 (fr) Derives de la quinazoline et leurs emplois
DK1063228T5 (da) Cycloalkenderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf
AU3191995A (en) Fused pyridazine compound
WO2002072578A3 (fr) Composes de quinoline heterocycliques contenant de l'azote
DK0711282T3 (da) Forbindelser som PDE IV og TNF inhibitorer
CA2080705A1 (fr) Derives de substitution de pyrimidines
EP0555478A4 (en) Pyrimidine derivative and medicine
ES548418A0 (es) Un procedimiento para preparar un compuesto de piperazina
WO2000068198A3 (fr) Derives de pyridine heterosubstitues utilises comme inhibiteurs de pde 4
NO941977L (no) Indolderivater, fremgangsmåte for fremstilling av disse, og medisinsk anvendelse derav
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
EP0434057A3 (en) Indolocarbazole derivatives, processes for their preparation and their use
PT96404A (pt) Processo para a preparacao de novos derivados de quinazolina e de composicoes farmaceuticas que os contem
CA2139731A1 (fr) 5-hydroxy-1,3 pyrimidines a groupement heterocyclique en position 2 utilises comme agents anti-inflammatoires
WO1993018769A3 (fr) Nouvelle utilisation d'un derive de quinazoline
EP0661274A1 (fr) Dérivés d'indane, procédé pour leur préparation et leurs intermédiaires de synthèse
WO2002062798A3 (fr) Sels de composes heterocycliques pharmaceutiquement acceptables
WO2000003978A3 (fr) Benzolsulfonyl-urees et -thiourees substituees en 2,5, leur procede de production, leur utilisation et les preparations pharmaceutiques les contenant
EP0201349A3 (fr) Dérivés de tétrazole
Foye et al. Antiradiation compounds XVI: N‐heterocyclic aminoethyl disulfides and aminoethanethiosulfuric acids
JPS5697226A (en) Blood platelet coagulation inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase